Millennium Management LLC trimmed its stake in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 32.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 209,611 shares of the company's stock after selling 100,366 shares during the period. Millennium Management LLC owned 0.12% of HUTCHMED worth $3,020,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of the stock. Bank of America Corp DE lifted its stake in HUTCHMED by 40.4% in the 4th quarter. Bank of America Corp DE now owns 22,723 shares of the company's stock valued at $327,000 after buying an additional 6,540 shares in the last quarter. Jane Street Group LLC increased its position in shares of HUTCHMED by 54.7% during the fourth quarter. Jane Street Group LLC now owns 97,470 shares of the company's stock worth $1,405,000 after purchasing an additional 34,473 shares in the last quarter. Marshall Wace LLP acquired a new stake in HUTCHMED during the 4th quarter worth $261,000. Barclays PLC boosted its position in HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after acquiring an additional 2,255 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in HUTCHMED by 18.4% during the 4th quarter. Renaissance Technologies LLC now owns 188,539 shares of the company's stock valued at $2,717,000 after acquiring an additional 29,239 shares in the last quarter. Institutional investors and hedge funds own 8.82% of the company's stock.
HUTCHMED Price Performance
HCM traded up $0.35 on Wednesday, hitting $15.05. The company had a trading volume of 29,893 shares, compared to its average volume of 89,807. HUTCHMED has a 1 year low of $11.51 and a 1 year high of $21.50. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. The company's fifty day moving average price is $14.05 and its 200 day moving average price is $14.82.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on HCM. Wall Street Zen lowered shares of HUTCHMED from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. HSBC downgraded HUTCHMED from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th.
Read Our Latest Report on HUTCHMED
About HUTCHMED
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Read More
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
